BioSpace News Archive

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2nd Annual TGFβ for Immuno-Oncology Drug Development Summit (January 25-27, 2022).

Reimagine Care, an innovative provider of technology-enabled services that supports oncologists in delivering high-quality, home-centered, value-based cancer care, today announced it has completed a $25 million capital raise led by Santé Ventures, Martin Ventures, and LRVHealth.

Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, announced the appointment of Carl Vause as its new chief executive officer and president.

Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG —Leaps by Bayer— 8VC, and Humboldt Fund.

Twist Bioscience Corporation and Artisan Development Labs Inc. today announced a collaboration to discover novel antibodies against five undisclosed targets.

Metagenomi today announced the completion of an up-sized and oversubscribed $175 million Series B financing.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference.

PTC Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted priority review of a supplemental new drug application for Evrysdi® to expand the indication to include pre-symptomatic infants under 2 months old with spinal muscular atrophy.

QIAGEN N.V. announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has dosed the first patient in a global Phase 2 clinical trial of MTL-CEBPA in combination with second line standard of care sorafenib ) in advanced hepatocellular carcinoma.